Discontinuation report HUMIRA

Last updated on 2020-06-29 History
Report ID 119141
Drug Identification Number 02258595
Brand name HUMIRA VIAL
Common or Proper name HUMIRA (ADALIMUMAB) VIAL
Company Name ABBVIE CORPORATION
Market Status MARKETED
Active Ingredient(s) ADALIMUMAB
Strength(s) 40MG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS
Packaging size 2 x 0.8mL vial (40mg/0.8mL)
ATC code L04AB
ATC description IMMUNOSUPPRESSANTS
Reason for discontinuation Business reasons
Anticipated discontinuation date 2020-12-30
Actual discontinuation date
Remaining supply date 2020-12-30
Discontinuation status To be discontinued
Discontinuation decision reversal No
Information on remaining supply Last HUMIRA vial lot available on market expires on June 2021. Per AbbVie’s return policy, the HUMIRA vial is a non-eligible product for credit.
Company comments The HUMIRA 40mg vial will be phased out by the end of December 2020. AbbVie will introduce the new HUMIRA 20 mg pre-filled syringe for pediatric patients prescribed HUMIRA 20mg. HUMIRA 40mg in PEN and pre-filled syringe are still available for pediatric patients prescribed HUMIRA 40mg / HUMIRA 40mg Vial sera discontinue à la fin Décembre 2020. AbbVie mettra sur le marché, le HUMIRA 20 mg seringues préremplies pour usage pédiatrique. HUMIRA 40mg auto-injecteur, est toujours disponible pour les patients pédiatriques prescrits avec HUMIRA 40mg.
Health Canada comments
Contact Address 8401 TRANS-CANADA HIGHWAY
SAINT-LAURENT, QUEBEC
CANADA H4S 1Z1
Company contact information Should you require any additional information, please contact our Customer Service Department at 1-888-704-8270.

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v1 2020-06-29 English Compare
v2 2020-06-29 French Compare
v3 2020-06-29 English Compare
v4 2020-06-29 English Compare